Atropine injection 0.1%, 1 ml No. 5

• Exacerbation of gastric ulcer and duodenal ulcer;

• acute pancreatitis;

• pylorospasm;

• spasms of the intestines, gallbladder and bile ducts, urinary tract, bronchi;

• laryngospasm (prevention);

• hypersalivation (parkinsonism, poisoning with salts of heavy metals);

• bradycardia;

• AV block;

• poisoning with cholinomimetic and anticholinesterase drugs;

• premedication before surgery.

For the relief of acute pain in stomach and duodenal ulcers and pancreatitis, renal, hepatic colic, etc.

The drug is administered subcutaneously or intramuscularly at 0.25-1 mg (0.25-1 ml of solution).

To eliminate bradycardia - intravenous in a dose of 0.5 - 1 mg, if necessary, after 5 minutes, the administration can be repeated.

For the purpose of premedication - in / m 0.4 - 0.6 mg 45 - 60 minutes before anesthesia.

For children, the drug is administered at a dose of 0.01 mg / kg.

In case of poisoning with m-cholinostimulants and anticholinesterase agents, 1.4 ml of a 0.1% solution intravenously (syringe tube) is administered, preferably in combination with cholinesterase reactivators.

1 ml of solution contains 1 mg or 0.5 mg of atropine sulfate.
Excipients: hydrochloric acid, water for injection.

• Hypersensitivity

• angle-closure glaucoma or a predisposition to it,

• tachyarrhythmias,

• severe congestive heart failure

• coronary heart disease,

• mitral stenosis,

• reflux esophagitis,

• hepatic and / or renal failure,

• intestinal atony,

• myasthenia gravis,

• hyperplasia of the prostate,

• obstructive bowel disease,

• paralytic ileus,

• toxic megacolon,

• nonspecific ulcerative colitis,

• hernia of the esophageal opening of the diaphragm.

With care
Hyperthermia, arterial hypertension. Hyperthyroidism, age over 40 (risk of manifestation of undiagnosed glaucoma).

Trade name of the drug: Atropine sulfate

International non-proprietary name: Atropine

Dosage form: Solution for injection.

Composition:
1 ml of solution contains 1 mg or 0.5 mg of atropine sulfate.
Excipients: hydrochloric acid, water for injection.

Description: clear, colorless liquid.

Pharmacotherapeutic group: M-anticholinergic antagonist

ATC code: ј03¬ј01

Pharmacological properties
An alkaloid contained in plants of the Solanaceae family, a blocker of M-cholinergic receptors, binds to the same extent with the m1-, m2- and m3-subtypes of muscarinic receptors. Affects both central and peripheral M-cholinergic receptors. It also acts (although much weaker) on n-cholinergic receptors. Interferes with the stimulating action of acetylcholine; reduces the secretion of salivary, gastric, bronchial, lacrimal, sweat glands, pancreas. Reduces muscle tone of internal organs (bronchi, gastrointestinal tract, bile ducts and gallbladder, urethra, bladder); causes tachycardia, improves AV conduction. Reduces the motility of the gastrointestinal tract, practically does not affect the secretion of bile. It dilates the pupils, hinders the outflow of intraocular fluid, increases intraocular pressure, and causes paralysis of accommodation.In medium therapeutic doses, it has a stimulating effect on the central nervous system and a delayed but long-term sedative effect; stimulates breathing (large doses - respiratory paralysis). Stimulates the cerebral cortex (in high doses), in toxic doses causes excitement, agitation, hallucinations, coma. Reduces the tone of the vagus nerve, which leads to an increase in heart rate (with a slight change in blood pressure) and a slight increase in conductivity in the His bundle. The effect is more pronounced with an initially increased tone of the vagus nerve.which leads to an increase in heart rate (with a slight change in blood pressure) and a slight increase in conductivity in the His bundle. The effect is more pronounced with an initially increased tone of the vagus nerve.which leads to an increase in heart rate (with a slight change in blood pressure) and a slight increase in conductivity in the His bundle. The effect is more pronounced with an initially increased tone of the vagus nerve.
After intravenous administration, the maximum effect appears after 2-4 minutes, after oral administration (in the form of drops) - after 30 minutes.

Pharmacokinetics. It is widely distributed in the body. It is metabolized in the liver by enzymatic hydrolysis. Communication with plasma proteins -18%. Penetrates the blood-brain barrier, placenta and breast milk. In significant concentrations, it is found in the central nervous system after 0.5-1 hours. The half-life is -2 hours.
Excretion by the kidneys is 50% unchanged, the rest is in the form of hydrolysis and conjugation products.

Indications for use

• Exacerbation of gastric ulcer and duodenal ulcer;

• acute pancreatitis;

• pylorospasm;

• spasms of the intestines, gallbladder and bile ducts, urinary tract, bronchi;

• laryngospasm (prevention);

• hypersalivation (parkinsonism, poisoning with salts of heavy metals);

• bradycardia;

• AV block;

• poisoning with cholinomimetic and anticholinesterase drugs;

• premedication before surgery.

Contraindications

• Hypersensitivity

• angle-closure glaucoma or a predisposition to it,

• tachyarrhythmias,

• severe congestive heart failure

• coronary heart disease,

• mitral stenosis,

• reflux esophagitis,

• hepatic and / or renal failure,

• intestinal atony,

• myasthenia gravis,

• hyperplasia of the prostate,

• obstructive bowel disease,

• paralytic ileus,

• toxic megacolon,

• nonspecific ulcerative colitis,

• hernia of the esophageal opening of the diaphragm.

With care
Hyperthermia, arterial hypertension. Hyperthyroidism, age over 40 (risk of manifestation of undiagnosed glaucoma).

Application during pregnancy and during breastfeeding

Atropine crosses the placental barrier. Adequate and strictly controlled clinical studies of the safety of atropine use during pregnancy have not been conducted. With intravenous administration of the drug during pregnancy or shortly before childbirth, the development of tachycardia in the fetus is possible.

It is not prescribed during pregnancy, complicated by preeclampsia. can lead to an increase in blood pressure. The use of the drug during breastfeeding is contraindicated.

The effect of the drug on the ability to drive vehicles, mechanisms

During the period of treatment, it is necessary to refrain from driving and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Method of administration and dosage

For the relief of acute pain in stomach and duodenal ulcers and pancreatitis, renal, hepatic colic, etc.

The drug is administered subcutaneously or intramuscularly at 0.25-1 mg (0.25-1 ml of solution).

To eliminate bradycardia - intravenous in a dose of 0.5 - 1 mg, if necessary, after 5 minutes, the administration can be repeated.

For the purpose of premedication - in / m 0.4 - 0.6 mg 45 - 60 minutes before anesthesia.

For children, the drug is administered at a dose of 0.01 mg / kg.

In case of poisoning with m-cholinostimulants and anticholinesterase agents, 1.4 ml of a 0.1% solution intravenously (syringe tube) is administered, preferably in combination with cholinesterase reactivators.

Side effect

Dry mouth, tachycardia, headache, dizziness, intestinal and bladder atony, constipation, difficulty urinating, photophobia, mydriasis, accommodation paralysis, increased intraocular pressure, xerostomia, impaired tactile perception.

Overdose

Symptoms Dryness of the mucous membrane of the oral cavity and nasopharynx, impaired swallowing and speech, dry skin, hyperthermia, mydriasis, etc. (see the section 'Side effects); motor and speech excitement, memory impairment, hallucinations, psychosis.
Treatment. Anticholinesterase and sedatives.

Drug interactions

Weakens the effect of m-cholinomimetics and anticholinesterase agents. Diphenhydramine or promethazine - enhancement of the action of atropine. Nitrates increase the likelihood of increased intraocular pressure. Procainamide - an increase in anticholinergic action.
Under the influence of guanethidine, a decrease in the hyposecretory action of atropine is possible.

Release form

Solution for injection 0.05% or 0.1%. 1 ml in neutral glass ampoules. 10 ampoules, together with instructions for use and a knife for opening ampoules or an ampoule scarifier, are placed in a cardboard box.
When using ampoules with notches, rings and break points, it is allowed not to insert the ampoule opening knife or ampoule scarifier.
5 ampoules in a blister strip made of polyvinyl chloride film and lacquered aluminum foil or without foil. 1 or 2 blisters, together with instructions for use, are placed in a cardboard box.

Storage conditions

Store in a dark place at a temperature of 2 to 30 ? C. Keep out of the reach of children.